![Farmak Tafamidis Meglumine](https://www.pharmacompass.com/image/flap/farmak-tafamidis-meglumine-header-desktopgif-42043.gif)
![Farmak Tafamidis Meglumine](https://www.pharmacompass.com/image/flap/farmak-tafamidis-meglumine-header-mobilegif-3470.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Analysis from the Phase 3 ATTR-ACT trial for VYNDAQEL (tafamidis meglumine) / VYNDAMAX® (tafamidis), oral transthyretin stabilizers showed a clinically significant 41% reduction in the risk of Heart Failure.
Lead Product(s): Tafamidis Meglumine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vyndamax
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021